Source: Virtual Congress 2020 – Pathophysiology and treatment of obstructive sleep apnoea
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
M. Meszaros (Budapest, Hungary), Z. Lazar (Budapest, Hungary), A. Tarnoki (Budapest, Hungary), D. Tarnoki (Budapest, Hungary), A. Kis (Budapest, Hungary), L. Kunos (Budapest, Hungary), A. Bikov (Manchester, United Kingdom). The role of hyaluronan metabolism in obstructive sleep apnoea. 1334

Member's Comments

No comment yet.

Related content which might interest you: The role of angiogenesis in obstructive sleep apnea (OSA) Source: Eur Respir J 2005; 26: Suppl. 49, 357s Year: 2005 The role of inflammatory biomarkers in obstructive sleep apnea syndrome Source: International Congress 2018 – Sleep-disordered breathing: biomarkers and genetics and the role of hypoxia, insomnia, movement disorders and sleep quality Year: 2018 Pathophysiological consequences of obstructive sleep apnoea Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases Year: 2006 The vascular micromilieu in obstructive sleep apnoea Source: Eur Respir J 2005; 25: 780-782 Year: 2005 Cortisol metabolism in obstructive sleep apnea (OSA) Source: Eur Respir J 2002; 20: Suppl. 38, 215s Year: 2002 Roles of periostin in patients with severe obstructive sleep apnea Source: International Congress 2017 – New pathophysiological insights: intermittent hypoxia, cardiopulmonary function and biomarkers Year: 2017 Local airway inflammation in obstructive sleep apnoea: the role of leptin Source: Eur Respir J 2006; 28: Suppl. 50, 645s Year: 2006 Glucose metabolism abnormalities in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA I Year: 2012 The puzzle of metabolic effects of obstructive sleep apnoea in children Source: Eur Respir J 2016; 47: 1050-1053 Year: 2016 The metabolic consequences of obstructive sleep apnoea in children Source: Breathe 2009; 6: 111-114 Year: 2009 Leptin in obstructive sleep apnea Source: Eur Respir J 2001; 18: Suppl. 33, 333s Year: 2001 Erythrocyte production in obstructive sleep apnea Source: Eur Respir J 2004; 24: Suppl. 48, 692s Year: 2004 The effect of concomitant COPD on obstructive sleep apnea syndrome severity and sleep structure Source: Annual Congress 2011 - Obstructive sleep apnoea as a comorbidity Year: 2011 The velumount device for obstructive sleep apnoea Source: Annual Congress 2009 - Assessment and therapeutical interventions in obstructive sleep apnoea Year: 2009 The impact of obstructive sleep apnoea on the aorta Source: Eur Respir J 2015; 46: 532-544 Year: 2015 Hepcidin: the new marker for determining nocturnal hypoxia in patients with obstructive sleep apnea Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing Year: 2009 Catecholamine secretion in obstructive sleep apnoea (OSA) Source: Eur Respir J 2005; 26: Suppl. 49, 38s Year: 2005 Can leptin be used to treat obstructive sleep apnoea? Source: International Congress 2019 – New horizons for pharmacotherapy of sleep-disordered breathing: from bench to bedside Year: 2019 Endothelial function in obstructive sleep apnea syndrome Source: Annual Congress 2011 - Cardiometabolic and neurocognitive changes in obstructive sleep apnoea Year: 2011 Does obstructive sleep apnoea predispose to reduced renal function? Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing Year: 2009